The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
Merus still hopes for a future for MCLA-129, but the doors are closing.